癌症支持治療藥物市場規模、佔有率和成長分析（按治療層級、應用、分銷管道和地區）- 產業預測 2025-2032

癌症支持治療藥物市場規模預計到 2023 年將達到 217.5 億美元，並從 2024 年的 224 億美元成長到 2032 年的 283.8 億美元，預測期內（2025-2032 年）的複合年成長率為 3.0%。

全球癌症支持護理藥物市場對於減輕癌症治療的副作用和改善患者的生活品質至關重要。癌症發病率的上升、人口老化以及癌症治療的突破性進展正在推動該領域的顯著成長。止吐藥、止痛藥和補血藥等支持性護理藥物對於控制噁心、疼痛和血球數低等副作用至關重要。正在進行的研究和開發重點是開發更有針對性的治療方法，製藥公司之間的合作正在擴大將支持治療與癌症治療相結合的治療選擇。隨著以患者為中心的照護變得越來越突出，以及人們認知到治療期間保持生活品質的重要性，推動創新並提高患者的舒適度，對這些藥物的需求預計將繼續成長。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 宏觀經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管格局
• 專利分析

癌症支持治療藥物市場規模（按治療層級和複合年成長率） (2025-2032)

• 市場概況
• 顆粒細胞增生因子（G-CSF）
• 促紅血球生成素促效劑 (ESA)
• 止吐藥
• 雙磷酸鹽
• 鴉片類藥物
• 非類固醇消炎劑(NSAID)

癌症支持治療藥物市場規模（按應用分類）及複合年成長率（2025-2032）

• 市場概況
• 化療引起的噁心和嘔吐 (CINV)
• 化療引起的貧血
• 化療引起的嗜中性白血球低下症
• 骨轉移
• 癌症痛
• 其他

癌症支持治療藥物市場規模（按分銷管道和複合年成長率）（2025-2032）

• 市場概況
• 醫院藥房
• 零售藥局
• 網路藥局

癌症支持治療藥物市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Amgen Inc.（USA）
• Merck & Co., Inc.（USA）
• Johnson & Johnson Services, Inc.（USA）
• Novartis AG（Switzerland）
• F. Hoffmann-La Roche AG（Switzerland）
• Sanofi（France）
• Pfizer Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Helsinn Healthcare（Switzerland）
• Heron Therapeutics, Inc.（USA）
• Acacia Pharma Group Plc（UK）
• Sun Pharmaceutical Industries Ltd.（India）
• Celldex Therapeutics（USA）
• Ipsen Pharma（France）
• GlaxoSmithKline plc（UK）
• Bayer AG（Germany）
• Takeda Pharmaceutical Company Limited（Japan）
• Mylan NV（USA）
• Dr. Reddy's Laboratories Ltd.（India）
• Eli Lilly and Company（USA）

結論和建議

Cancer Supportive Care Drugs Market size was valued at USD 21.75 billion in 2023 and is poised to grow from USD 22.4 billion in 2024 to USD 28.38 billion by 2032, growing at a CAGR of 3.0% during the forecast period (2025-2032).

The global market for cancer supportive care drugs is pivotal in alleviating the adverse effects of cancer treatments and enhancing patients' quality of life. With rising cancer incidence, an aging population, and breakthroughs in cancer therapies, this sector has experienced significant growth. Supportive care drugs, including antiemetics, analgesics, and hematopoietic agents, are essential in managing side effects such as nausea, pain, and low blood cell counts. Ongoing research and development efforts are focused on creating more targeted therapies, and collaborations among pharmaceutical companies are expanding treatment options to integrate supportive care with cancer treatments. As the focus on patient-centered care intensifies and the importance of maintaining quality of life during treatment gains recognition, demand for these drugs is expected to continue to grow, driving innovation and enhancing patient comfort.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cancer Supportive Care Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cancer Supportive Care Drugs Market Segments Analysis

Global Cancer Supportive Care Drugs Market is segmented by Therapeutic Class, Application, Distribution Channel and region. Based on Therapeutic Class, the market is segmented into Granulocyte Colony-Stimulating Factors (G-CSFs), Erythropoiesis-Stimulating Agents (ESAs), Antiemetics, Bisphosphonates, Opioids and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). Based on Application, the market is segmented into Chemotherapy-Induced Nausea and Vomiting (CINV), Chemotherapy-Induced Anemia, Chemotherapy-Induced Neutropenia, Bone Metastasis, Cancer Pain and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Cancer Supportive Care Drugs Market

The escalating incidence of cancer worldwide significantly drives the demand for cancer supportive care drugs. As more patients receive treatments such as chemotherapy, radiation therapy, and targeted therapies, the necessity to manage the adverse effects associated with these procedures becomes increasingly critical. Supportive care drugs play a vital role in enhancing patients' quality of life by alleviating symptoms such as nausea, pain, anemia, and fatigue, which often accompany cancer treatments. Consequently, the growing population of cancer patients seeking effective relief options underscores the importance of these drugs in the therapeutic landscape, further propelling market growth in the cancer supportive care segment.

Restraints in the Cancer Supportive Care Drugs Market

The high cost of cancer supportive care drugs presents a significant challenge in the market, potentially limiting their accessibility and usage. For many cancer patients, especially those in regions with limited healthcare insurance or inadequate government-funded healthcare programs, the financial burden can be overwhelming. This steep pricing may deter patients from utilizing these essential medications, which are crucial for managing treatment side effects. Consequently, this economic restraint can hinder effective cancer care, ultimately impacting patients' quality of life and their ability to cope with the rigorous demands of their treatment regimen.

Market Trends of the Cancer Supportive Care Drugs Market

The Cancer Supportive Care Drugs market is experiencing a significant trend towards personalized supportive care, driven by advancements in individualized cancer treatments. As therapies become more tailored to specific cancer types and patient characteristics, there is a growing demand for supportive care medications designed to alleviate unique side effects such as chemotherapy-induced nausea, vomiting, pain, fatigue, and anemia. This targeted approach enhances patient quality of life and fosters better treatment adherence, ultimately improving overall outcomes. With the increasing recognition of the importance of supportive care in holistic cancer management, the market is poised for robust growth, reflecting the evolving needs of patients and healthcare providers.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Cancer Supportive Care Drugs Market Size by Therapeutic Class & CAGR (2025-2032)

• Market Overview
• Granulocyte Colony-Stimulating Factors (G-CSFs)
• Erythropoiesis-Stimulating Agents (ESAs)
• Antiemetics
• Bisphosphonates
• Opioids
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Global Cancer Supportive Care Drugs Market Size by Application & CAGR (2025-2032)

• Market Overview
• Chemotherapy-Induced Nausea and Vomiting (CINV)
• Chemotherapy-Induced Anemia
• Chemotherapy-Induced Neutropenia
• Bone Metastasis
• Cancer Pain
• Others

Global Cancer Supportive Care Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Cancer Supportive Care Drugs Market Size & CAGR (2025-2032)

• North America (Therapeutic Class, Application, Distribution Channel)
  • US
  • Canada
• Europe (Therapeutic Class, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapeutic Class, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapeutic Class, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapeutic Class, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Helsinn Healthcare (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Heron Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acacia Pharma Group Plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celldex Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations